SG11201811643TA - Compounds and methods for modulating rna function - Google Patents

Compounds and methods for modulating rna function

Info

Publication number
SG11201811643TA
SG11201811643TA SG11201811643TA SG11201811643TA SG11201811643TA SG 11201811643T A SG11201811643T A SG 11201811643TA SG 11201811643T A SG11201811643T A SG 11201811643TA SG 11201811643T A SG11201811643T A SG 11201811643TA SG 11201811643T A SG11201811643T A SG 11201811643TA
Authority
SG
Singapore
Prior art keywords
international
massachusetts
pct
publication
methods
Prior art date
Application number
SG11201811643TA
Inventor
Russell C Petter
James Gregory Barsoum
Gnanasambandam Kumaravel
Kenneth W Bair
Original Assignee
Arrakis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrakis Therapeutics Inc filed Critical Arrakis Therapeutics Inc
Publication of SG11201811643TA publication Critical patent/SG11201811643TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111 0111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/006074 A3 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: C12N 15/113 (2010.01) C07K 2/00 (2006.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US2017/040514 claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 30 June 2017 (30.06.2017) (88) Date of publication of the international search report: (25) Filing Language: English 15 February 2018 (15.02.2018) (26) Publication Language: English (30) Priority Data: 62/357,654 01 July 2016 (01.07.2016) US 62/453,487 01 February 2017 (01.02.2017) US (71) Applicant: ARRAKIS THERAPEUTICS, INC. [US/US]; c/o Goodwin Procter 100 Northern Avenue, Boston, Massachusetts 02210 (US). (72) Inventors: PETTER, Russell C.; 22 Robinwood Lane, Stow, Massachusetts 01775 (US). BARSOUM, James _ Gregory; 6 Moreland Avenue, Lexington, Massachusetts 02421 (US). KUMARAVEL, Gnanasambandam; 21 Ap- pletree Lane, Lexington, Massachusetts 02420 (US). BAIR, = = Kenneth W.; 41 Cartwright Road, Wellesley, Massachu- _ setts 02482 (US). = (74) Agent: REID, Andrea L.C. et al.; One International = Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US). Designated States (unless otherwise indicated, for every _ (81) = kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, _ = _ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = (84) Designated States (unless otherwise indicated, for every = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — M 71' MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). IN 0 0 0 --.... 00 1-1 (54) 0 Title: COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION ei (57) : The present invention provides compounds, compositions thereof, and methods of using the same.
SG11201811643TA 2016-07-01 2017-06-30 Compounds and methods for modulating rna function SG11201811643TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357654P 2016-07-01 2016-07-01
US201762453487P 2017-02-01 2017-02-01
PCT/US2017/040514 WO2018006074A2 (en) 2016-07-01 2017-06-30 Compounds and methods for modulating rna function

Publications (1)

Publication Number Publication Date
SG11201811643TA true SG11201811643TA (en) 2019-01-30

Family

ID=60786563

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811643TA SG11201811643TA (en) 2016-07-01 2017-06-30 Compounds and methods for modulating rna function

Country Status (11)

Country Link
US (2) US20190194150A1 (en)
EP (1) EP3478842A4 (en)
JP (1) JP2019523242A (en)
CN (1) CN109563515A (en)
AU (1) AU2017290894A1 (en)
CA (1) CA3028446A1 (en)
IL (2) IL263943A (en)
MX (1) MX2018016038A (en)
RU (1) RU2018145144A (en)
SG (1) SG11201811643TA (en)
WO (1) WO2018006074A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3230473B1 (en) 2014-12-08 2020-04-29 The Regents Of The University Of Michigan Non-coding rnas and uses thereof
KR102636384B1 (en) 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for modulating splicing
US10815484B2 (en) 2017-11-22 2020-10-27 The Regents Of The University Of Michigan Compositions and methods for treating cancer
RU2020112854A (en) 2017-11-30 2021-12-30 Арракис Терапьютикс, Инк. PHOTOPROBES BINDING NUCLEIC ACIDS AND METHODS OF THEIR APPLICATION
JP2021535737A (en) * 2018-03-23 2021-12-23 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Methods and assays for regulating gene transcription by regulating condensates
WO2019199733A1 (en) * 2018-04-10 2019-10-17 The Regents Of The University Of Michigan Compositions and methods for treating cancer
US20200017514A1 (en) * 2018-07-12 2020-01-16 Michael Plewe Adamantane derivatives for the treatment of filovirus infection
CN109928933B (en) * 2019-01-10 2021-02-26 安徽昊帆生物有限公司 2-chloro-5-aldehyde pyrimidine and preparation method thereof
KR20210135241A (en) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for controlling splicing
KR20210135507A (en) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for controlling splicing
JP2022519523A (en) 2019-02-08 2022-03-24 デューポイント セラピューティクス， インコーポレイテッド Methods and Uses for characterization of Condensate-Related Properties of Compounds
US20220073910A1 (en) * 2019-02-12 2022-03-10 The Scripps Research Institute A Cross-Linking Approach to Map Small Molecule-RNA Binding Sites in Cells
EP4031876A1 (en) 2019-09-18 2022-07-27 Dewpoint Therapeutics, Inc. Methods of screening for condensate-associated specificity and uses thereof
CN110782945B (en) * 2019-10-22 2023-07-18 长沙学院 Method for identifying association of lncRNA and diseases by using indirect and direct characteristic information
WO2023094412A1 (en) * 2021-11-25 2023-06-01 Merck Patent Gmbh Materials for electronic devices
WO2023205694A2 (en) * 2022-04-20 2023-10-26 Tacit Therapeutics, Inc. Stabilization of therapeutic trans-splicing rna molecules in human cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296775A1 (en) * 2000-10-06 2002-04-15 Kansas State University Research Foundation Triptycene analogs
US9150612B2 (en) * 2007-02-23 2015-10-06 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
US9260476B2 (en) * 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
FR2968302B1 (en) * 2010-12-06 2012-11-30 Biomerieux Sa METHODS OF FUNCTIONALIZATION AND REAGENTS USED IN SUCH METHODS USING ISATOIC ANHYDRIDE OR ONE OF ITS DERIVATIVES, BIOLOGIC MOLECULES SO TREATED AND KITS
EP2670404B1 (en) * 2011-02-02 2018-08-29 The Trustees of Princeton University Sirtuin modulators as virus production modulators
EP3352872A4 (en) * 2015-09-24 2019-07-10 The Trustees of the University of Pennsylvania Triptycene derivatives for nucleic acid junction stabilization
CA3012700A1 (en) * 2016-02-01 2017-08-10 Arrakis Therapeutics, Inc. Compounds and methods of treating rna-mediated diseases

Also Published As

Publication number Publication date
AU2017290894A1 (en) 2019-01-17
IL263943A (en) 2019-01-31
US20220402883A1 (en) 2022-12-22
US20190194150A1 (en) 2019-06-27
WO2018006074A2 (en) 2018-01-04
EP3478842A2 (en) 2019-05-08
CN109563515A (en) 2019-04-02
RU2018145144A3 (en) 2020-09-14
JP2019523242A (en) 2019-08-22
WO2018006074A3 (en) 2018-02-15
MX2018016038A (en) 2019-05-13
RU2018145144A (en) 2020-08-03
CA3028446A1 (en) 2018-01-04
IL285229A (en) 2021-09-30
EP3478842A4 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201909710XA (en) Indole ahr inhibitors and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201909011PA (en) Niraparib compositions
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201808014SA (en) Compositions, devices, and methods for cell separation
SG11201808682XA (en) Silicone atoms containing ivacaftor analogues
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201809751XA (en) Egfr inhibitor compounds
SG11201903892UA (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201811671XA (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis